Potency of non-steroidal anti-inflammatory drugs in chemotherapy (Review)
- Authors:
- Lucia Hiľovská
- Rastislav Jendželovský
- Peter Fedoročko
-
Affiliations: Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice, 040 01 Košice, Slovakia - Published online on: October 16, 2014 https://doi.org/10.3892/mco.2014.446
- Pages: 3-12
This article is mentioned in:
Abstract
 |
|
Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, Shiff SI and Rigas B: Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol. 52:237–245. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Souza RF, Shewmake K, Beer DG, Cryer B and Spechler SJ: Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. 60:5767–5772. 2000.PubMed/NCBI | |
|
Dai Y and Wang WH: Non-steroidal anti-inflammatory drugs in prevention of gastric cancer. World J Gastroenterol. 12:2884–2889. 2006.PubMed/NCBI | |
|
DuBois RN and Smalley WE: Cyclooxygenase, NSAIDs, and colorectal cancer. J Gastroenterol. 31:898–906. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Rao CV and Reddy BS: NSAIDs and chemoprevention. Curr Cancer Drug Targets. 4:29–42. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Winde G, Schmid KW, Brandt B, Muller O and Osswald H: Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. Dis Colon Rectum. 40:1156–1169. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Maclagan T: The treatment of acute rheumatism by salicin and salicylic acid. Lancet. 113:875–877. 1879. View Article : Google Scholar | |
|
Dugowson CE and Gnanashanmugam P: Nonsteroidal anti-inflammatory drugs. Phys Med Rehabil Clin N Am. 17347–354. (vi)2006. View Article : Google Scholar | |
|
Vane JR and Botting RM: The mechanism of action of aspirin. Thromb Res. 110:255–258. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Flower RJ: Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev. 26:33–67. 1974. | |
|
Vane JR and Botting RM: Anti-inflammatory drugs and their mechanism of action. Inflamm Res. 47 (Suppl 2):S78–S87. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Marnett LJ, Rowlinson SW, Goodwin DC, Kalgutkar AS and Lanzo CA: Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J Biol Chem. 274:22903–22906. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Rao P and Knaus EE: Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 11:S81–S110. 2008.PubMed/NCBI | |
|
Dubois RN, Abramson SB, Crofford L, et al: Cyclooxygenase in biology and disease. FASEB J. 12:1063–1073. 1998.PubMed/NCBI | |
|
Rigas B and Shiff SJ: Nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenases, and the cell cycle. Their interactions in colon cancer. Adv Exp Med Biol. 470:119–126. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Wang D, Mann JR and DuBois RN: The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology. 128:1445–1461. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Capdevila JH, Falck JR and Harris RC: Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res. 41:163–181. 2000.PubMed/NCBI | |
|
Gerritsen ME: Physiological and pathophysiological roles of eicosanoids in the microcirculation. Cardiovasc Res. 32:720–732. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Harder DR, Campbell WB and Roman RJ: Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone. J Vasc Res. 32:79–92. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Harizi H, Corcuff JB and Gualde N: Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol Med. 14:461–469. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Chen YQ, Duniec ZM, Liu B, et al: Endogenous 12(S)-HETE production by tumor cells and its role in metastasis. Cancer Res. 54:1574–1579. 1994.PubMed/NCBI | |
|
Gao X, Grignon DJ, Chbihi T, et al: Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology. 46:227–237. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Honn KV, Tang DG, Gao X, et al: 12-lipoxygenases and 12(S)-HETE: role in cancer metastasis. Cancer Metastasis Rev. 13:365–396. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Tang DG and Honn KV: 12-Lipoxygenase, 12(S)-HETE, and cancer metastasis. Ann N Y Acad Sci. 744:199–215. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Timar J, Raso E, Fazakas ZS, Silletti S, Raz A and Honn KV: Multiple use of a signal transduction pathway in tumor cell invasion. Anticancer Res. 16:3299–3306. 1996.PubMed/NCBI | |
|
Kage K, Fujita N, Oh-hara T, Ogata E, Fujita T and Tsuruo T: Basic fibroblast growth factor induces cyclooxygenase-2 expression in endothelial cells derived from bone. Biochem Biophys Res Commun. 254:259–263. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Fong CY, Pang L, Holland E and Knox AJ: TGF-beta1 stimulates IL-8 release, COX-2 expression, and PGE(2) release in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 279:L201–L207. 2000.PubMed/NCBI | |
|
Saha D, Datta PK, Sheng H, et al: Synergistic induction of cyclooxygenase-2 by transforming growth factor-beta1 and epidermal growth factor inhibits apoptosis in epithelial cells. Neoplasia. 1:508–517. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Diaz A, Chepenik KP, Korn JH, Reginato AM and Jimenez SA: Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts. Exp Cell Res. 241:222–229. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Chandrasekharan NV, Dai H, Roos KL, et al: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA. 99:13926–13931. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Cui JG, Kuroda H, Chandrasekharan NV, et al: Cyclooxygenase-3 gene expression in Alzheimer hippocampus and in stressed human neural cells. Neurochem Res. 29:1731–1737. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Kis B, Snipes JA and Busija DW: Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties. J Pharmacol Exp Ther. 315:1–7. 2005. View Article : Google Scholar | |
|
Cerella C, Sobolewski C, Chateauvieux S, et al: COX-2 inhibitors block chemotherapeutic agent-induced apoptosis prior to commitment in hematopoietic cancer cells. Biochem Pharmacol. 82:1277–1290. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Surh YJ and Kundu JK: Signal transduction network leading to COX-2 induction: a road map in search of cancer chemopreventives. Arch Pharm Res. 28:1–15. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S and DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107:1183–1188. 1994.PubMed/NCBI | |
|
Sano H, Kawahito Y, Wilder RL, et al: Expression of cyclooxygenase-1 and −2 in human colorectal cancer. Cancer Res. 55:3785–3789. 1995. | |
|
Ristimaki A, Honkanen N, Jankala H, Sipponen P and Harkonen M: Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57:1276–1280. 1997.PubMed/NCBI | |
|
Yip-Schneider MT, Barnard DS, Billings SD, et al: Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 21:139–146. 2000. | |
|
Wilson KT, Fu S, Ramanujam KS and Meltzer SJ: Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res. 58:2929–2934. 1998. | |
|
Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H and Ristimaki A: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58:4997–5001. 1998.PubMed/NCBI | |
|
Hwang D, Scollard D, Byrne J and Levine E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 90:455–460. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Cao Y and Prescott SM: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol. 190:279–286. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Hida T, Kozaki K, Muramatsu H, et al: Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res. 6:2006–2011. 2000.PubMed/NCBI | |
|
O'Kane SL, Eagle GL, Greenman J, Lind MJ and Cawkwell L: COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines. Lung Cancer. 67:160–165. 2010.PubMed/NCBI | |
|
Sinha-Datta U, Taylor JM, Brown M and Nicot C: Celecoxib disrupts the canonical apoptotic network in HTLV-I cells through activation of Bax and inhibition of PKB/Akt. Apoptosis. 13:33–40. 2008. View Article : Google Scholar | |
|
Totzke G, Schulze-Osthoff K and Janicke RU: Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene. 22:8021–8030. 2003. View Article : Google Scholar | |
|
Elder DJ, Halton DE, Hague A and Paraskeva C: Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res. 3:1679–1683. 1997. | |
|
Grosch S, Tegeder I, Niederberger E, Brautigam L and Geisslinger G: COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 15:2742–2744. 2001.PubMed/NCBI | |
|
Zhang X, Morham SG, Langenbach R and Young DA: Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med. 190:451–459. 1999. View Article : Google Scholar | |
|
Pidgeon GP, Lysaght J, Krishnamoorthy S, et al: Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev. 26:503–524. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Radmark O, Werz O, Steinhilber D and Samuelsson B: 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci. 32:332–341. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Werz O and Steinhilber D: Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol Ther. 112:701–718. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Wasilewicz MP, Kolodziej B, Bojulko T, et al: Overexpression of 5-lipoxygenase in sporadic colonic adenomas and a possible new aspect of colon carcinogenesis. Int J Colorectal Dis. 25:1079–1085. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Metzger K, Angres G, Maier H and Lehmann WD: Lipoxygenase products in human saliva: patients with oral cancer compared to controls. Free Radic Biol Med. 18:185–194. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Hu Y, Zhang H, Peng C and Li S: Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet. 41:783–792. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hennig R, Ventura J, Segersvard R, et al: LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice. Neoplasia. 7:417–425. 2005.PubMed/NCBI | |
|
Paruchuri S, Broom O, Dib K and Sjolander A: The pro-inflammatory mediator leukotriene D4 induces phosphatidylinositol 3-kinase and Rac-dependent migration of intestinal epithelial cells. J Biol Chem. 280:13538–13544. 2005. View Article : Google Scholar | |
|
Hayashi T, Nishiyama K and Shirahama T: Inhibition of 5-lipoxygenase pathway suppresses the growth of bladder cancer cells. Int J Urol. 13:1086–1091. 2006. | |
|
Meng Z, Cao R, Yang Z, Liu T, Wang Y and Wang X: Inhibitor of 5-lipoxygenase, zileuton, suppresses prostate cancer metastasis by upregulating E-cadherin and paxillin. Urology. 82(1452): e7–e14. 2013.PubMed/NCBI | |
|
Schroeder CP, Yang P, Newman RA and Lotan R: Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines. J Exp Ther Oncol. 6:183–192. 2007. | |
|
Shin VY, Jin HC, Ng EK, Sung JJ, Chu KM and Cho CH: Activation of 5-lipoxygenase is required for nicotine mediated epithelial-mesenchymal transition and tumor cell growth. Cancer Lett. 292:237–245. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hagmann W, Gao X, Zacharek A, Wojciechowski LA and Honn KV: 12-Lipoxygenase in Lewis lung carcinoma cells: molecular identity, intracellular distribution of activity and protein, and Ca2+-dependent translocation from cytosol to membranes. Prostaglandins. 49:49–62. 1995.PubMed/NCBI | |
|
Pidgeon GP, Kandouz M, Meram A and Honn KV: Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res. 62:2721–2727. 2002.PubMed/NCBI | |
|
Tang DG, Chen YQ and Honn KV: Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci USA. 93:5241–5246. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Wong BC, Wang WP, Cho CH, et al: 12-Lipoxygenase inhibition induced apoptosis in human gastric cancer cells. Carcinogenesis. 22:1349–1354. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Terada N, Shimizu Y, Kamba T, et al: Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. Cancer Res. 70:1606–1615. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang WG, Watkins G, Douglas-Jones A and Mansel RE: Reduction of isoforms of 15-lipoxygenase (15-LOX)-1 and 15-LOX-2 in human breast cancer. Prostaglandins Leukot Essent Fatty Acids. 74:235–245. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Shappell SB, Boeglin WE, Olson SJ, Kasper S and Brash AR: 15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol. 155:235–245. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Shureiqi I, Wu Y, Chen D, et al: The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res. 65:11486–11492. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Tang DG, Bhatia B, Tang S and Schneider-Broussard R: 15-Lipoxygenase 2 (15-LOX2) is a functional tumor suppressor that regulates human prostate epithelial cell differentiation, senescence, and growth (size). Prostaglandins Other Lipid Mediat. 82:135–146. 2007. View Article : Google Scholar | |
|
Bhatia B, Tang S, Yang P, et al: Cell-autonomous induction of functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) contributes to replicative senescence of human prostate progenitor cells. Oncogene. 24:3583–3595. 2005. View Article : Google Scholar | |
|
Tang S, Bhatia B, Maldonado CJ, et al: Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells. J Biol Chem. 277:16189–16201. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Brown CM, Reisfeld B and Mayeno AN: Cytochromes P450: a structure-based summary of biotransformations using representative substrates. Drug Metab Rev. 40:1–100. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cheranov SY, Karpurapu M, Wang D, Zhang B, Venema RC and Rao GN: An essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis. Blood. 111:5581–5591. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang JG, Ning YG, Chen C, et al: Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res. 67:6665–6674. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Webler AC, Michaelis UR, Popp R, et al: Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis. Am J Physiol Cell Physiol. 295:C1292–C1301. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Webler AC, Popp R, Korff T, et al: Cytochrome P450 2C9-induced angiogenesis is dependent on EphB4. Arterioscler Thromb Vasc Biol. 28:1123–1129. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yan G, Chen S, You B and Sun J: Activation of sphingosine kinase-1 mediates induction of endothelial cell proliferation and angiogenesis by epoxyeicosatrienoic acids. Cardiovasc Res. 78:308–314. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Turk D and Szakacs G: Relevance of multidrug resistance in the age of targeted therapy. Curr Opin Drug Discov Devel. 12:246–252. 2009.PubMed/NCBI | |
|
Arico S, Pattingre S, Bauvy C, et al: Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem. 277:27613–27621. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Arunasree KM, Roy KR, Anilkumar K, Aparna A, Reddy GV and Reddanna P: Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. Leuk Res. 32:855–864. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Roy KR, Reddy GV, Maitreyi L, et al: Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line. Cancer Chemother Pharmacol. 65:903–911. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yu L, Wu WK, Li ZJ, Liu QC, Li HT, Wu YC and Cho CH: Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity. Mol Pharmacol. 75:1364–1373. 2009. | |
|
Zatelli MC, Luchin A, Tagliati F, et al: Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. Endocr Relat Cancer. 14:1029–1038. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
de Vries EF, Doorduin J, Vellinga NA, van Waarde A, Dierckx RA and Klein HC: Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study. Nucl Med Biol. 35:459–466. 2008.PubMed/NCBI | |
|
Awara WM, El-Sisi AE, El-Sayad ME and Goda AE: The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin? Pharmacol Res. 50:487–498. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Yan YX, Li WZ, Huang YQ and Liao WX: The COX-2 inhibitor celecoxib enhances the sensitivity of KB/VCR oral cancer cell lines to vincristine by down-regulating P-glycoprotein expression and function. Prostaglandins Other Lipid Mediat. 97:29–35. 2011. View Article : Google Scholar | |
|
Zrieki A, Farinotti R and Buyse M: Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm Res. 25:1991–2001. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ye CG, Wu WK, Yeung JH, et al: Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression. Cancer Lett. 304:90–96. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kang HK, Lee E, Pyo H and Lim SJ: Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. Mol Cancer Ther. 4:1358–1363. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Ko SH, Choi GJ, Lee JH, Han YA, Lim SJ and Kim SH: Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma. Oncol Rep. 19:425–433. 2008. | |
|
Natarajan K, Xie Y, Baer MR and Ross DD: Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol. 83:1084–1103. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Elahian F, Kalalinia F and Behravan J: Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines. Drug Chem Toxicol. 33:113–119. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chen M, Yu L, Gu C, Zhong D, Wu S and Liu S: Celecoxib antagonizes the cytotoxic effect of cisplatin in human gastric cancer cells by decreasing intracellular cisplatin accumulation. Cancer Lett. 329:189–196. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sugiura T, Saikawa Y, Kubota T, et al: Combination chemotherapy with JTE-522, a novel selective cyclooxygenase-2 inhibitor, and cisplatin against gastric cancer cell lines in vitro and in vivo. In Vivo. 17:229–233. 2003. | |
|
Kim SH, Kim SH, Song YC and Song YS: Celecoxib potentiates the anticancer effect of cisplatin on vulvar cancer cells independently of cyclooxygenase. Ann N Y Acad Sci. 1171:635–641. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Li WZ, Wang XY, Li ZG, Zhang JH and Ding YQ: Celecoxib enhances the inhibitory effect of cisplatin on Tca8113 cells in human tongue squamous cell carcinoma in vivo and in vitro. J Oral Pathol Med. 39:579–584. 2010.PubMed/NCBI | |
|
van Wijngaarden J, van Beek E, van Rossum G, et al: Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation. Eur J Cancer. 43:433–442. 2007. | |
|
Xia W, Zhao T, Lv J, et al: Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner. J Cell Biochem. 108:181–194. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Pereira MA, Tao L, Wang W, et al: Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors. Carcinogenesis. 25:1917–1923. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ellinger J, Bastian PJ, Jurgan T, et al: CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology. 71:161–167. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Enokida H, Shiina H, Igawa M, et al: CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res. 64:5956–5962. 2004. View Article : Google Scholar | |
|
Qiu YY, Mirkin BL and Dwivedi RS: MDR1 hypermethylation contributes to the progression of neuroblastoma. Mol Cell Biochem. 301:131–135. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL and Xie K: Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res. 64:2030–2038. 2004. View Article : Google Scholar | |
|
Cianchi F, Cortesini C, Magnelli L, et al: Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol Cancer Ther. 5:2716–2726. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
El-Awady RA, Saleh EM, Ezz M and Elsayed AM: Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells. Toxicol Appl Pharmacol. 255:271–286. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chen C, Shen HL, Yang J, Chen QY and Xu WL: Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib. J Cancer Res Clin Oncol. 137:9–17. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Fosslien E: Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci. 30:3–21. 2000.PubMed/NCBI | |
|
Bol DK, Rowley RB, Ho CP, et al: Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development. Cancer Res. 62:2516–2521. 2002.PubMed/NCBI | |
|
Nakopoulou L, Mylona E, Papadaki I, et al: Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma. Pathobiology. 72:241–249. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Z, Choudhary S, Voznesensky O, et al: Overexpression of COX-2 in human osteosarcoma cells decreases proliferation and increases apoptosis. Cancer Res. 66:6657–6664. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Patel VA, Dunn MJ and Sorokin A: Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem. 277:38915–38920. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Saikawa Y, Sugiura T, Toriumi F, et al: Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15. Anticancer Res. 24:2723–2728. 2004.PubMed/NCBI | |
|
Surowiak P, Materna V, Matkowski R, et al: Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res. 7:R862–R870. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Surowiak P, Pawelczyk K, Maciejczyk A, et al: Positive correlation between cyclooxygenase 2 and the expression of ABC transporters in non-small cell lung cancer. Anticancer Res. 28:2967–2974. 2008.PubMed/NCBI | |
|
Ziemann C, Schafer D, Rudell G, Kahl GF and Hirsch-Ernst KI: The cyclooxygenase system participates in functional MDR1b overexpression in primary rat hepatocyte cultures. Hepatology. 35:579–588. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Liu B, Qu L and Tao H: Cyclo-oxygenase 2 up-regulates the effect of multidrug resistance. Cell Biol Int. 34:21–25. 2010.PubMed/NCBI | |
|
Jendzelovsky R, Mikes J, Koval J, et al: Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells. Photochem Photobiol Sci. 8:1716–1723. 2009. View Article : Google Scholar | |
|
Kleban J, Mikes J, Horvath V, et al: Mechanisms involved in the cell cycle and apoptosis of HT-29 cells pre-treated with MK-886 prior to photodynamic therapy with hypericin. J Photochem Photobiol B. 93:108–118. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kleban J, Mikes J, Szilardiova B, et al: Modulation of hypericin photodynamic therapy by pretreatment with 12 various inhibitors of arachidonic acid metabolism in colon adenocarcinoma HT-29 cells. Photochem Photobiol. 83:1174–1185. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kleban J, Szilardiova B, Mikes J, et al: Pre-treatment of HT-29 cells with 5-LOX inhibitor (MK-886) induces changes in cell cycle and increases apoptosis after photodynamic therapy with hypericin. J Photochem Photobiol B. 84:79–88. 2006. View Article : Google Scholar | |
|
Hida T, Kozaki K, Ito H, et al: Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res. 8:2443–2447. 2002. | |
|
Hossain MA, Kim DH, Jang JY, et al: Aspiri. induces apoptosis in vitro and inhibits tumor growth of human hepatocellular carcinoma cells in a nude mouse xenograft model. Int J Oncol. 40:1298–1304. 2012.PubMed/NCBI | |
|
Irie T, Tsujii M, Tsuji S, et al: Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma. Int J Cancer. 121:878–883. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Knapp DW, Glickman NW, Widmer WR, et al: Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol. 46:221–226. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Ponthan F, Wickstrom M, Gleissman H, et al: Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res. 13:1036–1044. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Spugnini EP, Cardillo I, Verdina A, et al: Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res. 12:6133–6143. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang DQ, Guo Q, Zhu JH and Chen WC: Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer. World J Surg Oncol. 11(16)2013. View Article : Google Scholar | |
|
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M and DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:705–716. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT and Masferrer JL: Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 62:625–631. 2002.PubMed/NCBI | |
|
Patel MI, Subbaramaiah K, Du B, et al: Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res. 11:1999–2007. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Sakamoto T, Uozaki H, Kondo K, et al: Cyclooxygenase-2 regulates the degree of apoptosis by modulating bcl-2 protein in pleomorphic adenoma and mucoepidermoid carcinoma of the parotid gland. Acta Otolaryngol. 125:191–195. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Tjiu JW, Liao YH, Lin SJ, et al: Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis. J Invest Dermatol. 126:1143–1151. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Wang F, Sun GP, Zou YF, et al: Expression of COX-2 and Bcl-2 in primary fallopian tube carcinoma: correlations with clinicopathologic features. Folia Histochem Cytobiol. 49:389–397. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Stark LA, Din FV, Zwacka RM and Dunlop MG: Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J. 15:1273–1275. 2001. | |
|
Park IS, Jo JR, Hong H, et al: Aspirin induces apoptosis in YD-8 human oral squamous carcinoma cells through activation of caspases, down-regulation of Mcl-1, and inactivation of ERK-1/2 and AKT. Toxicol In Vitro. 24:713–720. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Stark LA, Reid K, Sansom OJ, et al: Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis. 28:968–976. 2007. View Article : Google Scholar | |
|
Trifan OC, Durham WF, Salazar VS, et al: Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res. 62:5778–5784. 2002.PubMed/NCBI | |
|
Altorki NK, Port JL, Zhang F, et al: Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer. Clin Cancer Res. 11:4191–4197. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Masferrer JL, Leahy KM, Koki AT, et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60:1306–1311. 2000.PubMed/NCBI | |
|
Kohne CH, De Greve J, Hartmann JT, et al: Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol. 19:920–926. 2008. View Article : Google Scholar | |
|
Maiello E, Giuliani F, Gebbia V, et al: Gruppo Oncologico dell'Italia Meridionale, FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol. 17 (Suppl 7):vii55–59. 2006. | |
|
Schneider BJ, Kalemkerian GP, Kraut MJ, et al: Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy. J Thorac Oncol. 3:1454–1459. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Skapek SX, Anderson JR, Hill DA, et al: Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study. Pediatr Blood Cancer. 60:1108–1112. 2013.PubMed/NCBI | |
|
Csiki I, Morrow JD, Sandler A, et al: Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clin Cancer Res. 11:6634–6640. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Becerra CR, Frenkel EP, Ashfaq R and Gaynor RB: Increased toxicity and lack of efficacy of rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: a phase II study. Int J Cancer. 105:868–872. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Dang CT, Dannenberg AJ, Subbaramaiah K, et al: Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res. 10:4062–4067. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Gridelli C, Gallo C, Ceribelli A, et al: Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol. 8:500–512. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Groen HJ, Sietsma H, Vincent A, et al: Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol. 29:4320–4326. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Koch A, Bergman B, Holmberg E, et al Swedish Lung Cancer Study Group: Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. Eur J Cancer. 47:1546–1555. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Altorki NK, Keresztes RS, Port JL, et al: Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol. 21:2645–2650. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Nugent FW, Mertens WC, Graziano S, et al: Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial. Lung Cancer. 48:267–273. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Legge F, Paglia A, D'Asta M, Fuoco G, Scambia G and Ferrandina G: Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients. BMC Cancer. 11(214)2011. View Article : Google Scholar : PubMed/NCBI | |
|
Altorki NK, Christos P, Port JL, et al: Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial. J Thorac Oncol. 6:1121–1127. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
An Y and Ongkeko WM: ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol. 5:1529–1542. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Huang WZ, Fu JH, Wang DK, et al: Overexpression of cyclooxygenase-2 is associated with chemoradiotherapy resistance and prognosis in esophageal squamous cell carcinoma patients. Dis Esophagus. 21:679–684. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Robey RW, To KK, Polgar O, et al: ABCG2: a perspective. Adv Drug Deliv Rev. 61:3–13. 2009. View Article : Google Scholar | |
|
Szczuraszek K, Materna V, Halon A, et al: Positive correlation between cyclooxygenase-2 and ABC-transporter expression in non-Hodgkin's lymphomas. Oncol Rep. 22:1315–1323. 2009.PubMed/NCBI | |
|
Edelman MJ, Watson D, Wang X, et al: Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy - Cancer and Leukemia Group B Trial 30203. J Clin Oncol. 26:848–855. 2008.PubMed/NCBI |
